The Role of Orexin Signaling in the Ventral Tegmental Area and Central Amygdala in Modulating Binge-Like Ethanol Drinking Behavior

Alcohol Clin Exp Res. 2017 Mar;41(3):551-561. doi: 10.1111/acer.13336. Epub 2017 Feb 9.

Abstract

Background: Recent reports have demonstrated that binge-like ethanol (EtOH) drinking leads to an increase in hypothalamic orexin (OX) signaling and that suppressing this signaling via systemic administration of an orexin receptor (OXR) antagonist blocks this behavior; however, the specific OX pathways that modulate this behavior remain unknown. The goal of this study was to further elucidate the role of the OX system in binge-like EtOH drinking using behavioral, molecular, and pharmacological techniques.

Methods: The drinking-in-the-dark (DID) paradigm was used to model binge-like drinking behavior in male C57BL/6J mice. Experiment 1 examined changes in the OX precursor, prepro-orexin, within the hypothalamus following multiple cycle EtOH or sucrose DID using polymerase chain reaction (PCR) analysis. In experiments 2a and 2b, we used site-directed infusion of an OXR antagonist to examine the individual contribution of each OXR subtype within the ventral tegmental area (VTA) and central nucleus of the amygdala (CeA), respectively, in binge-like EtOH or sucrose drinking.

Results: Findings from our PCR study revealed that multiple cycles of binge-like EtOH drinking did not lead to changes in prepro-orexin mRNA as a function of binge-like EtOH drinking. However, data from site-directed pharmacology studies indicate that the orexin-1 receptor (OX1R) is the predominate receptor subtype within the VTA and CeA that regulates binge-like EtOH drinking. Interestingly, inhibition of OX1Rs did not affect binge-like sucrose intake, which suggests that these OX circuits are specific for EtOH consumption.

Conclusions: As a whole, these data suggest that the VTA and CeA are important regions in which OX regulates binge-like EtOH drinking behavior. Moreover, these findings identify OXR antagonists as a potential treatment option that may be used to ameliorate problematic drinking behavior while leaving responding to natural rewards relatively intact.

Keywords: Binge Ethanol Drinking; Drinking in the Dark; Hypocretin; Orexin.

MeSH terms

  • Animals
  • Benzoxazoles / administration & dosage
  • Binge Drinking / drug therapy
  • Binge Drinking / metabolism*
  • Central Amygdaloid Nucleus / drug effects
  • Central Amygdaloid Nucleus / physiology*
  • Ethanol / administration & dosage*
  • Injections, Intraventricular
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Naphthyridines
  • Orexin Receptor Antagonists / administration & dosage
  • Orexin Receptors / physiology*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Urea / administration & dosage
  • Urea / analogs & derivatives
  • Ventral Tegmental Area / drug effects
  • Ventral Tegmental Area / physiology*

Substances

  • 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea
  • Benzoxazoles
  • Naphthyridines
  • Orexin Receptor Antagonists
  • Orexin Receptors
  • Ethanol
  • Urea